Education
About Us
Working with TipRanks
Follow Us
Bioventus (BVS)
NASDAQ:BVS
Total Valuation
Bioventus has a market cap or net worth of $542.15M. The enterprise value is $546.48M.
Market Cap$542.15M
Enterprise Value$546.48M
Share Statistics
Bioventus has 66,357,610 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding66,357,610
Owned by Insiders32.15%
Owned by Institutions45.71%
Financial Efficiency
Bioventus’s return on equity (ROE) is -0.23 and return on invested capital (ROIC) is -1.96%.
Return on Equity (ROE)-0.23
Return on Assets (ROA)-0.05
Return on Invested Capital (ROIC)-1.96%
Return on Capital Employed (ROCE)-0.02
Revenue Per Employee616.43K
Profits Per Employee0.00
Employee Count930
Asset Turnover0.79
Inventory Turnover2.00
Valuation Ratios
The current PE Ratio of Bioventus is -20.46. Bioventus’s PEG ratio is <0.01.
PE Ratio-20.46
PS Ratio0.00
PB Ratio0.51
Price to Fair Value4.64
Price to FCF-6.39
Price to Operating Cash Flow-11.84
PEG Ratio<0.01
Income Statement
In the last 12 months, Bioventus had revenue of 573.28M and earned -33.54M in profits. Earnings per share was -0.75.
Revenue573.28M
Gross Profit388.23M
Operating Income-11.98M
Pretax Income-49.13M
Net Income-33.54M
EBITDA-49.55M
Earnings Per Share (EPS)-0.75
Cash Flow
In the last 12 months, operating cash flow was 25.47M and capital expenditures -1.54M, giving a free cash flow of 23.93M billion.
Operating Cash Flow25.47M
Free Cash Flow23.93M
Free Cash Flow per Share0.36
Dividends & Yields
Bioventus pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.91
52-Week Price Change14.82%
50-Day Moving Average6.97
200-Day Moving Average9.89
Relative Strength Index (RSI)40.53
Average Volume (3m)414.91K
Important Dates
Bioventus upcoming earnings date is Aug 12, 2025, TBA Not Confirmed.
Last Earnings DateMay 6, 2025
Next Earnings DateAug 12, 2025
Ex-Dividend Date―
Financial Position
Bioventus as a current ratio of 1.31, with Debt / Equity ratio of 132.06%
Current Ratio1.31
Quick Ratio0.87
Debt to Market Cap0.49
Net Debt to EBITDA-5.93
Interest Coverage Ratio-0.31
Taxes
In the past 12 months, Bioventus has paid -5.29M in taxes.
Income Tax-5.29M
Effective Tax Rate0.11
Enterprise Valuation
Bioventus EV to EBITDA ratio is -19.78, with an EV/FCF ratio of 25.94.
EV to Sales1.71
EV to EBITDA-19.78
EV to Free Cash Flow25.94
EV to Operating Cash Flow25.27
Balance Sheet
Bioventus has $22.80M in cash and marketable securities with $345.93M in debt, giving a net cash position of $323.13M billion.
Cash & Marketable Securities$22.80M
Total Debt$345.93M
Net Cash$323.13M
Net Cash Per Share$4.87
Tangible Book Value Per Share-$3.47
Margins
Gross margin is 64.65%, with operating margin of -2.09%, and net profit margin of -5.85%.
Gross Margin64.65%
Operating Margin-2.09%
Pretax Margin-8.57%
Net Profit Margin-5.85%
EBITDA Margin-8.64%
EBIT Margin-1.80%
Analyst Forecast
The average price target for Bioventus is $11.00, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
Price Target$11.00
Price Target Upside73.23% Upside
Analyst ConsensusModerate Buy
Analyst Count3
Revenue Growth Forecast8.60%
EPS Growth Forecast-42.76%